Supplemental Online Content


eFigure 1. Overall Survival in RT + Icotinib Group
eFigure 2. Overall Survival in RT Group
eTable 1. Univariate Analysis of Potential Factors Associated With Survival in all ESCC Patients
eTable 2. Multivariate Analysis of Prognostic Factors in all ESCC Patients
eTable 3. Patterns of First Failure Between Two Groups of Elderly ESCC Patients

This supplemental material has been provided by the authors to give readers additional information about their work.
**eFigure 1. Overall Survival in RT + Icotinib Group**

Overall Survival in the RT + Icotinib Group

- **EGFR:3+**
- **EGFR:0.1-2+**

<table>
<thead>
<tr>
<th>Time since randomisation (months)</th>
<th>Overall Survival (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>5</td>
<td>100</td>
</tr>
<tr>
<td>10</td>
<td>100</td>
</tr>
<tr>
<td>15</td>
<td>100</td>
</tr>
<tr>
<td>20</td>
<td>100</td>
</tr>
<tr>
<td>25</td>
<td>100</td>
</tr>
<tr>
<td>30</td>
<td>100</td>
</tr>
<tr>
<td>35</td>
<td>100</td>
</tr>
<tr>
<td>40</td>
<td>100</td>
</tr>
<tr>
<td>45</td>
<td>100</td>
</tr>
<tr>
<td>50</td>
<td>100</td>
</tr>
</tbody>
</table>

HR: 0.62 (95% CI: 0.38 - 0.96)

*p = 0.032*

**Number at Risk**

<table>
<thead>
<tr>
<th>EGFR:3+</th>
<th>7</th>
<th>6</th>
<th>6</th>
<th>6</th>
<th>6</th>
<th>6</th>
<th>5</th>
<th>0</th>
<th>0</th>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGFR:0.1-2+</td>
<td>25</td>
<td>22</td>
<td>16</td>
<td>13</td>
<td>12</td>
<td>10</td>
<td>9</td>
<td>7</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>
eFigure 2. Overall Survival in RT Group

HR: 0.36 (95% CI: 0.31 - 4.01)  
*p = 0.2

<table>
<thead>
<tr>
<th>Time since randomisation (months)</th>
<th>Overall Survival (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>5</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td></td>
</tr>
<tr>
<td>35</td>
<td></td>
</tr>
<tr>
<td>40</td>
<td></td>
</tr>
<tr>
<td>45</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td></td>
</tr>
</tbody>
</table>

Number at Risk

<table>
<thead>
<tr>
<th></th>
<th>EGFR.3+</th>
<th>EGFR.01-2+</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1</td>
<td>28</td>
</tr>
<tr>
<td>5</td>
<td>1</td>
<td>22</td>
</tr>
<tr>
<td>10</td>
<td>1</td>
<td>19</td>
</tr>
<tr>
<td>15</td>
<td>1</td>
<td>17</td>
</tr>
<tr>
<td>20</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>25</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>30</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>35</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>40</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>45</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>50</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

# Table 1. Univariate Analysis of Potential Factors Associated With Survival in all ESCC Patients

<table>
<thead>
<tr>
<th>Factors</th>
<th>HR</th>
<th>95%CI-low</th>
<th>95%CI-up</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>TKI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No TKI</td>
<td>reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TKI</td>
<td>1.739</td>
<td>1.146</td>
<td>2.638</td>
<td>.009</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>.663</td>
<td>.430</td>
<td>1.020</td>
<td>.061</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>70 ≤ age &lt; 75</td>
<td>reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75 ≤ age &lt; 80</td>
<td>.893</td>
<td>.532</td>
<td>1.499</td>
<td>.669</td>
</tr>
<tr>
<td>Age ≥ 80</td>
<td>.842</td>
<td>.491</td>
<td>1.444</td>
<td>.532</td>
</tr>
<tr>
<td>T stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>.431</td>
<td>.229</td>
<td>.812</td>
<td>.009</td>
</tr>
<tr>
<td>4</td>
<td>.582</td>
<td>.347</td>
<td>.977</td>
<td>.040</td>
</tr>
<tr>
<td>N stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>.746</td>
<td>.491</td>
<td>1.135</td>
<td>.171</td>
</tr>
<tr>
<td>ECOG</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-1</td>
<td>reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>.780</td>
<td>.518</td>
<td>1.175</td>
<td>.235</td>
</tr>
<tr>
<td>Location</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervical esophagus</td>
<td>reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper-third</td>
<td>.488</td>
<td>.184</td>
<td>1.294</td>
<td>.149</td>
</tr>
<tr>
<td>Middle-third</td>
<td>.572</td>
<td>.303</td>
<td>1.079</td>
<td>.084</td>
</tr>
<tr>
<td>Lower-third</td>
<td>1.074</td>
<td>.648</td>
<td>1.780</td>
<td>.781</td>
</tr>
<tr>
<td>Tumor length</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;5</td>
<td>reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥5</td>
<td>.657</td>
<td>.430</td>
<td>1.004</td>
<td>.052</td>
</tr>
<tr>
<td>EGFR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-2</td>
<td>reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>.427</td>
<td>.15</td>
<td>1.2</td>
<td>.106</td>
</tr>
</tbody>
</table>

Abbreviation: ESCC, esophageal squamous cell carcinoma; HR, hazard ratio; CI: confidence interval; TKI: tyrosine kinase inhibitor; ECOG: Eastern Cooperative Oncology Group performance status.
### eTable 2. Multivariate Analysis of Prognostic Factors in all ESCC Patients

<table>
<thead>
<tr>
<th>Factors</th>
<th>HR</th>
<th>95%CI-low</th>
<th>95%CI-up</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>TKI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No TKI</td>
<td>Reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TKI</td>
<td>1.703</td>
<td>1.090</td>
<td>2.662</td>
<td>.019</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>Reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>.804</td>
<td>.507</td>
<td>1.274</td>
<td>.353</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>70 ≤ age &lt; 75</td>
<td>Reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75 ≤ age &lt; 80</td>
<td>1.201</td>
<td>.682</td>
<td>2.117</td>
<td>.526</td>
</tr>
<tr>
<td>Age ≥ 80</td>
<td>.962</td>
<td>.554</td>
<td>1.673</td>
<td>.892</td>
</tr>
<tr>
<td>T</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>.465</td>
<td>.240</td>
<td>.902</td>
<td>.023</td>
</tr>
<tr>
<td>4</td>
<td>.644</td>
<td>.378</td>
<td>1.095</td>
<td>.104</td>
</tr>
<tr>
<td>N</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>Reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>.664</td>
<td>.413</td>
<td>1.068</td>
<td>.092</td>
</tr>
<tr>
<td>ECOG</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-1</td>
<td>Reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>.812</td>
<td>.523</td>
<td>1.259</td>
<td>.352</td>
</tr>
<tr>
<td>Location</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervical esophagus</td>
<td>Reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper-third</td>
<td>.544</td>
<td>.191</td>
<td>1.555</td>
<td>.256</td>
</tr>
<tr>
<td>Middle-third</td>
<td>.542</td>
<td>.268</td>
<td>1.094</td>
<td>.087</td>
</tr>
<tr>
<td>Lower-third</td>
<td>1.043</td>
<td>.612</td>
<td>1.779</td>
<td>.876</td>
</tr>
<tr>
<td>Tumor length(cm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;5</td>
<td>Reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥5</td>
<td>.784</td>
<td>.492</td>
<td>1.249</td>
<td>.306</td>
</tr>
</tbody>
</table>

Abbreviation: ESCC, esophageal squamous cell carcinoma; HR, hazard ratio; CI: confidence interval; TKI: tyrosine kinase inhibitor; ECOG: Eastern Cooperative Oncology Group performance status
### eTable 3. Patterns of First Failure Between Two Groups of Elderly ESCC Patients

<table>
<thead>
<tr>
<th></th>
<th>RT group (N=63)</th>
<th>RT+icotinib group (N=64)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Local recurrence</td>
<td>36 (57.1%)</td>
<td>24 (37.5%)</td>
</tr>
<tr>
<td>Regional recurrence</td>
<td>4 (6.3%)</td>
<td>3 (4.7%)</td>
</tr>
<tr>
<td>Distant metastasis</td>
<td>10 (15.9%)</td>
<td>4 (6.3%)</td>
</tr>
<tr>
<td>Both local and regional</td>
<td>2 (3.2%)</td>
<td>1 (1.6%)</td>
</tr>
<tr>
<td>Both local/regional and distant failure</td>
<td>7 (11.1%)</td>
<td>4 (6.3%)</td>
</tr>
</tbody>
</table>

Values are number (%) unless otherwise stated.

Abbreviation: ESCC, esophageal squamous cell carcinoma; RT, radiation therapy.